Echosens Presents Research at 2021 AASLD Liver Meeting: Early Detection and Monitoring with FibroScan Mitigates Risk of Patients Developing Fibrosis/Cirrhosis
11.11.2021 16:53:00 EET | Business Wire | Press release
Echosens, a high-technology company offering the FibroScan® family of products, is pleased to announce its strong presence at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, a digital conference, Nov. 12-15, 2021, with FibroScan-based solutions - referenced in 19 oral presentations and 180 poster presentations. They include new results demonstrating the clinical usefulness of liver and spleen stiffness measurement by VCTE as well as CAP but also further confirm the performances of Fast™, Agile 3+, Agile 4 and FibroMeter VCTE scores in many different settings.
“Non-invasive FibroScan is an innovative technology that advances efforts to halt the progression of fatty liver disease (FLD) and empowers healthcare providers with an accurate, point-of-care tool to measure liver fat and stiffness,” says Dominique Legros, Group CEO, Echosens. “Our technology solutions serve as the cornerstone of non-invasive tests for the future of liver disease management—across the liver care continuum and all population groups. With better assessment tools in primary care, unnecessary specialist referrals and more invasive and expensive diagnostic testing can be reduced.”
FLD includes nonalcoholic fatty liver disease (NAFLD), the accumulation of liver fat in people who drink little or no alcohol, and its more severe form nonalcoholic steatohepatitis (NASH).
NAFLD is often present as a comorbidity in patients with Type 2 diabetes. The mutual interrelationship between these conditions shows that Type 2 diabetes can exacerbate NAFLD by promoting progression to NASH, often leading to fibrosis and cirrhosis, while NAFLD causes the natural course of diabetic complications to worsen in Type 2 diabetes patients.
NAFLD affects about 25% of people in the world. As the rates of obesity, Type 2 diabetes and high cholesterol rise, so does the rate of NAFLD. FibroScan is acknowledged worldwide and validated by over 3,000 peer reviewed publications and 140 international guidelines across 100+ countries.
Jon Gingrich, CEO, Echosens North America, says, “This important conference allows us to showcase FibroScan as a valuable innovation that can improve care and reduce costs for managing chronic liver conditions. The expanding body of data supports FibroScan as an early assessment and monitoring tool that can mitigate the risk that patients will develop more serious conditions like fibrosis, cirrhosis and liver cancer.”
About Echosens
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,000 peer reviewed publications and 140 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005332/en/
Contact information
Media:
Brittany Tedesco
CPR Communications
btedesco@cpronline.com
201.641.1911 x 14
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
What Europeans Really Want From Their Next Smartphone13.10.2026 14:01:00 EEST | Press release
If you’ve ever bought running shoes for the runner you hoped to become or luggage for a yet to be planned trip, you’re not alone. New research from Samsung reveals that Europeans1 take a similar aspirational approach when choosing a smartphone. More than two thirds (66%2) of Europeans surveyed1 chose their current smartphone with at least one interest they wanted to pursue in mind, with interests ranging from entertainment and side hustles to gaming, travel and content creation. In fact, almost half (46%3) consider their ambitions when making technology choices, including 24% who say their choices are primarily shaped by the life they aspire to lead. Additionally, almost a third (28%) reported that they chose their current smartphone to better reflect their personal style. Having a variety of options to choose from is important when considering the wide range of aspirations and focuses of European consumers. Big ambitions, everyday needs Europeans1 may be choosing smartphones with futu
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules13.10.2026 14:00:00 EEST | Press release
Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has entered into a research collaboration and license agreement with Pfizer Inc. to discover and develop Sec61 inhibitors. The collaboration aims to accelerate the discovery and advancement of novel small-molecule therapeutics leveraging Enodia’s proprietary platform. Enodia’s proprietary platform enables selective Sec61 Translocon modulation, a novel approach to inhibit disease-driving proteins at the point of synthesis before pathological effects occur, while preserving essential physiological functions. Enodia has built a broad and well-characterized chemical space spanning multiple Sec61 inhibitor families, supported by extensive biological datasets, including proteomics, cryo-EM and tailored cell-line libraries that enable rational small-molecule design powered by machine learning. “Enodia has built a broad platform t
TradingHub Appoints Phil Snow as Chairman13.10.2026 12:00:00 EEST | Press release
TradingHub today announced the appointment of Phil Snow as Chairman, further strengthening the company's leadership as it continues to expand its global presence and invest in innovation across trade surveillance. Phil brings three decades of experience in financial technology, data and analytics, built at FactSet, where he served as Chief Executive Officer from 2015 to 2025. Under his leadership, FactSet more than doubled its revenue, joined the S&P 500 and expanded its products and global presence. The appointment follows TradingHub's recent investment from Nordic Capital and reflects the shared ambition to support the company's next phase of growth while building on the strong foundations established by its leadership team. "Phil is an outstanding appointment for TradingHub, and I am delighted to welcome him as Chairman," said Mike Coats, Chief Executive Officer of TradingHub. "He spent a decade running a global financial data company that serves many of the same institutions we do,
Bregal Milestone Backs Asolvi to Build AI-First Field Service Software for Compliance-Critical Industries13.10.2026 11:00:00 EEST | Press release
Bregal Milestone, a leading European growth private equity firm specialising in software, today announced a majority investment in Asolvi, a provider of field service management (FSM) software for compliance-critical and asset-intensive industries. Bregal Milestone is acquiring its stake from Volpi Capital and Viking Growth. CEO Nick Barnett and the management team are reinvesting alongside Bregal Milestone. Founded in 1991 and headquartered in Trondheim, Norway, Asolvi serves more than 2,000 customers across the UK, DACH, the Nordics, Spain and Latin America. For fire and security installers and utility contractors, Asolvi’s software is the operating system of the business. It schedules engineers, manages maintenance contracts, records inspections, and produces evidence that regulators, insurers and building owners require. Because Asolvi sits at the centre of these workflows, it captures structured data on assets, inspections, parts, and outcomes as jobs are completed. This puts Asol
YouHodler Italy Authorised by CONSOB as a Crypto-Asset Service Provider Under MiCA13.10.2026 10:00:00 EEST | Press release
YouHodler Italy S.r.l., announces that CONSOB, after hearing the Bank of Italy, has authorised it as a crypto-asset service provider (CASP) under Regulation (EU) 2023/1114 (MiCA) and Legislative Decree 129/2024, by resolution no. 24156 of 8 October 2026. The authorisation covers five services: custody and administration of crypto-assets on behalf of clients; exchange of crypto-assets for funds; exchange of crypto-assets for other crypto-assets; execution of orders on behalf of clients; and transfer services for crypto-assets on behalf of clients. With the authorisation, YouHodler Italy serves clients in Italy as a supervised firm under MiCA's client protections: segregation of client crypto-assets, governance and security requirements, pre-contractual information and complaints handling. The company plans to extend its services to all 27 EU Member States through the procedure set out in the Regulation. "The CONSOB authorisation is the result of long and rigorous work with the authoriti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom